RU2016151115A - Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент - Google Patents
Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент Download PDFInfo
- Publication number
- RU2016151115A RU2016151115A RU2016151115A RU2016151115A RU2016151115A RU 2016151115 A RU2016151115 A RU 2016151115A RU 2016151115 A RU2016151115 A RU 2016151115A RU 2016151115 A RU2016151115 A RU 2016151115A RU 2016151115 A RU2016151115 A RU 2016151115A
- Authority
- RU
- Russia
- Prior art keywords
- infection
- agent
- infections
- paragraphs
- spp
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title claims 5
- 239000000853 adhesive Substances 0.000 title claims 4
- 230000000181 anti-adherent effect Effects 0.000 title claims 4
- 239000002270 dispersing agent Substances 0.000 title claims 4
- 230000003115 biocidal effect Effects 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title claims 2
- 208000015181 infectious disease Diseases 0.000 claims 15
- 238000000034 method Methods 0.000 claims 6
- 241000894006 Bacteria Species 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 230000000813 microbial effect Effects 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 241001453380 Burkholderia Species 0.000 claims 2
- 206010017964 Gastrointestinal infection Diseases 0.000 claims 2
- 206010065764 Mucosal infection Diseases 0.000 claims 2
- 241000589516 Pseudomonas Species 0.000 claims 2
- 241000191940 Staphylococcus Species 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 108010078777 Colistin Proteins 0.000 claims 1
- 208000006558 Dental Calculus Diseases 0.000 claims 1
- 208000001860 Eye Infections Diseases 0.000 claims 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- 241000606790 Haemophilus Species 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 241000186429 Propionibacterium Species 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 206010062255 Soft tissue infection Diseases 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 206010048038 Wound infection Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 229960003346 colistin Drugs 0.000 claims 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical group NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 1
- 239000004053 dental implant Substances 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 208000019836 digestive system infectious disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 208000011323 eye infectious disease Diseases 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 208000022760 infectious otitis media Diseases 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229960003151 mercaptamine Drugs 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960000707 tobramycin Drugs 0.000 claims 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Materials For Medical Uses (AREA)
- Dental Preparations (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (27)
1. Продукт, содержащий антибиотический агент и второй агент, представляющий собой диспергирующее средство или антиадгезивный агент.
2. Продукт по п. 1, не содержащий пептид.
3. Продукт по п. 1 или 2, где антибиотический агент представляет собой непептидный антибиотик.
4. Продукт по п. 3, где антибиотик представляет собой тобрамицин, колистин, гентамицин или ципрофлоксацин.
5. Продукт по любому из пп. 1-4, где второй агент представляет собой цистеамин.
6. Продукт по любому из пп. 1-5, содержащий синергетически эффективное количество (1) антибиотического агента и (2) второго агента, представляющего собой диспергирующее средство или антиадгезивный агент.
7. Продукт по любому из пп. 1-6 для применения в качестве лекарственного средства.
8. Субстрат, на который продукт по любому из пп. 1-7 наносят или на котором его фиксируют.
9. Субстрат по п. 8, выбранный из группы, состоящей из повязок, медицинских устройств и имплантированных устройств.
10. Субстрат по п. 9, где имплантированное устройство выбрано из группы, состоящей из стентов, катетеров, трубок для перитонеального диализа, дренирующих устройств, протезов суставов и зубных имплантатов.
11. Фармацевтическая композиция, содержащая продукт по любому из пп. 1-7 и один или более фармацевтически приемлемых разбавителей, эксципиентов и/или носителей.
12. Применение продукта по любому из пп. 1-7 в лечении или предупреждении микробной инфекции или ассоциированных с ней заболевания или состояния.
13. Применение по п. 12, где инфекция или ассоциированные с ней заболевание или состояние выбраны из группы, состоящей из кожных и раневых инфекций, инфекций среднего уха, инфекций желудочно-кишечного тракта, инфекций перитонеальной мембраны, инфекций мочеполового тракта, инфекций мягких тканей полости рта, образования зубного камня, глазных инфекций, эндокардита, инфекций при муковисцидозе и инфекций имплантированных медицинских устройств.
14. Применение по п. 12 или 13, где инфекция находится в муколитической среде.
15. Применение по п. 14, где инфекция представляет собой бактериальную инфекцию, ассоциированную с муковисцидозом.
16. Применение по любому из пп. 12-15, где инфекция вызвана бактерией, выбранной из группы, состоящей из Pseudomonas spp., Staphylococcus spp., Haemophilus spp., Burkholderia spp., Streptococcus spp.и Propionibacterium spp.
17. Применение по п. 16, где бактерия представляет собой Pseudomonas spp.
18. Применение по п. 16, где бактерия представляет собой Burkholderia spp.
19. Применение по п. 16, где бактерия представляет собой Staphylococcus spp.
20. Способ лечения микробной инфекции посредством профилактики или терапии, включающий последовательное или совместное введение в терапевтически эффективном количестве:
- антибиотического агента и
- второго агента, представляющего собой диспергирующее средство или антиадгезивный агент.
21. Способ по п. 20, включающий введение продукта по любому из пп. 1-7 или композиции по п. 11.
22. Способ по п. 20 или 21, где микробная инфекция представляет собой местную инфекцию или системную инфекцию.
23. Способ по п. 22, где системная инфекция представляет собой инфекцию слизистой оболочки.
24. Способ по п. 23, где инфекция слизистой оболочки представляет собой желудочно-кишечную инфекцию, инфекцию мочеполового тракта или респираторную инфекцию.
25. Способ по п. 23 или 24, где инфекция слизистой оболочки представляет собой муковисцидоз или ассоциирована с хронической обструктивной болезнью легких (COPD).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42300010P | 2010-12-14 | 2010-12-14 | |
| US61/423.000 | 2010-12-14 | ||
| GBGB1021186.0A GB201021186D0 (en) | 2010-12-14 | 2010-12-14 | Composition |
| US61/423,000 | 2010-12-14 | ||
| GB1021186.0 | 2010-12-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013131391A Division RU2607660C2 (ru) | 2010-12-14 | 2011-12-14 | Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016151115A true RU2016151115A (ru) | 2018-11-14 |
| RU2016151115A3 RU2016151115A3 (ru) | 2020-06-18 |
| RU2739249C2 RU2739249C2 (ru) | 2020-12-22 |
Family
ID=43567164
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013131391A RU2607660C2 (ru) | 2010-12-14 | 2011-12-14 | Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент |
| RU2016151115A RU2739249C2 (ru) | 2010-12-14 | 2011-12-14 | Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013131391A RU2607660C2 (ru) | 2010-12-14 | 2011-12-14 | Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9782423B2 (ru) |
| EP (2) | EP2651419B1 (ru) |
| JP (2) | JP5964854B2 (ru) |
| KR (1) | KR101955636B1 (ru) |
| CN (1) | CN103732232B (ru) |
| AU (3) | AU2011343012C1 (ru) |
| BR (2) | BR122019015601B1 (ru) |
| CA (1) | CA2821032C (ru) |
| CY (2) | CY1117447T1 (ru) |
| DK (2) | DK3040076T3 (ru) |
| ES (2) | ES2856831T3 (ru) |
| GB (1) | GB201021186D0 (ru) |
| HK (2) | HK1185015A1 (ru) |
| HR (2) | HRP20160235T1 (ru) |
| HU (2) | HUE027207T2 (ru) |
| IL (2) | IL226879B (ru) |
| LT (1) | LT3040076T (ru) |
| MX (1) | MX346664B (ru) |
| NZ (1) | NZ613076A (ru) |
| PL (2) | PL2651419T3 (ru) |
| PT (1) | PT3040076T (ru) |
| RS (2) | RS61469B1 (ru) |
| RU (2) | RU2607660C2 (ru) |
| SG (3) | SG10201703290UA (ru) |
| SI (2) | SI3040076T1 (ru) |
| SM (1) | SMT201600121B (ru) |
| UA (1) | UA114470C2 (ru) |
| WO (1) | WO2012080700A1 (ru) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8513305B2 (en) | 2007-05-14 | 2013-08-20 | Research Foundation Of State University Of New York | Induction of a physiological dispersion response in bacterial cells in a biofilm |
| GB0905451D0 (en) * | 2009-03-31 | 2009-05-13 | Novabiotics Ltd | Biofilms |
| GB201021186D0 (en) | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
| PT106094A (pt) | 2012-01-13 | 2013-07-15 | Hovione Farmaciencia S A | Administração por inalação de formulações com dose elevada |
| US20150273025A1 (en) * | 2012-09-28 | 2015-10-01 | The Regents Of The University Of Michigan | Apyrase treatments |
| GB201416727D0 (en) * | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
| GB201416716D0 (en) * | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
| US10617703B2 (en) | 2014-12-10 | 2020-04-14 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| GB201510077D0 (en) * | 2015-06-10 | 2015-07-22 | Novabiotics Ltd | Use |
| US10898455B2 (en) | 2016-01-07 | 2021-01-26 | Cmpd Licensing, Llc | Urea cream formulations |
| US11690815B2 (en) | 2015-08-05 | 2023-07-04 | Cmpd Licensing Llc | Hyperkeratotic skin condition treatments and compositions |
| US10898491B2 (en) | 2015-12-18 | 2021-01-26 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11278590B2 (en) | 2015-08-05 | 2022-03-22 | Cmpd Licensing, Llc | Compositions and methods for treating nail infections |
| US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| AU2016408394B2 (en) | 2016-05-26 | 2021-11-11 | Kimberly-Clark Worldwide, Inc. | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
| GB201609940D0 (en) * | 2016-06-07 | 2016-07-20 | Novabiotics Ltd | Microparticles |
| US10905660B2 (en) | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
| WO2017212239A1 (en) * | 2016-06-07 | 2017-12-14 | Novabiotics Limited | Treatment of drug-resistant microbial infections |
| WO2018093364A1 (en) * | 2016-11-16 | 2018-05-24 | The Regents Of The University Of California | Formulations of cysteamine and cystamine |
| US11737975B2 (en) | 2016-11-17 | 2023-08-29 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US11986448B2 (en) | 2016-11-17 | 2024-05-21 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US10525025B2 (en) | 2016-11-17 | 2020-01-07 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US10966946B2 (en) | 2016-11-17 | 2021-04-06 | Cmpd Licensing, Llc | Compounded compositions and methods for treating pain |
| US9999604B2 (en) | 2016-11-17 | 2018-06-19 | Cmpd Licensing, Llc | Compounded solutions of diclofenac and lidocaine and methods |
| RS64201B1 (sr) * | 2016-12-15 | 2023-06-30 | Zambon Spa | N-acetilcistein za upotrebu kao antibakterijsko sredstvo |
| EP3366284A1 (en) | 2017-02-27 | 2018-08-29 | Zambon S.p.A. | Association of n-acetylcysteine and colistin for use in bacterial infections |
| WO2018189687A1 (en) * | 2017-04-10 | 2018-10-18 | The University Of North Carolina At Chapel Hill | Compounds, compositions and methods for inhibiting a pathogen and/or modifying mucus |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| CA3116637A1 (en) * | 2018-10-17 | 2020-04-23 | Novabiotics Limited | Dosage regime |
| US20220265583A1 (en) * | 2019-07-30 | 2022-08-25 | The Regents Of The University Of California | Methods and composition for treating respiratory obstructive diseases |
| CN111053696B (zh) * | 2019-11-19 | 2022-11-04 | 温州医科大学附属口腔医院 | 一种抑制细菌粘附的超疏水凝胶纳米涂层及制备方法 |
| CN113018443B (zh) * | 2019-12-27 | 2022-09-13 | 海南斯达制药有限公司 | 治疗呼吸系统疾病的药物组合物及其制备方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1055560B (it) | 1974-05-02 | 1982-01-11 | Istituto Chemioterapico | Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali |
| US4051842A (en) | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
| DE2626348C3 (de) | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
| US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
| IT1178869B (it) | 1984-03-07 | 1987-09-16 | Cagliero Germano | Prodotto per prevenire e combattere le tossicosi alimentari dovute a micotossine |
| US4962091A (en) | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
| WO1994007529A1 (en) | 1992-09-25 | 1994-04-14 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| JP3749279B2 (ja) | 1995-03-01 | 2006-02-22 | 日産化学工業株式会社 | 爪用抗真菌剤 |
| US5624704A (en) * | 1995-04-24 | 1997-04-29 | Baylor College Of Medicine | Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent |
| US6086921A (en) | 1995-04-25 | 2000-07-11 | Wintrop-University Hospital | Metal/thiol biocides |
| US6461607B1 (en) * | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
| AU2042200A (en) | 1998-12-07 | 2000-06-26 | Baylor College Of Medicine | Preventing and removing biofilm from the surface of medical devices |
| UA80393C2 (ru) | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице |
| ITMI20021881A1 (it) | 2002-09-04 | 2004-03-05 | Zambon Spa | Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario. |
| GB2398497A (en) | 2003-02-19 | 2004-08-25 | Walcom Animal Science | Composition for improving immunity of animals |
| MXPA06007100A (es) | 2003-12-19 | 2007-01-19 | Omega Bio Pharma Ip3 Ltd | Composiciones y metodos para tratar la diabetes. |
| SG155211A1 (en) | 2004-08-18 | 2009-09-30 | Novabiotics Ltd | Peptide |
| WO2007050565A2 (en) * | 2005-10-25 | 2007-05-03 | Baylor College Of Medicine | Incorporation of antimicrobial combinations onto devices to reduce infection |
| CN101340902B (zh) | 2005-11-28 | 2011-01-26 | 奥加生物药业（香港）有限公司 | 用半胱胺化合物处理病毒感染的材料和方法 |
| AR057623A1 (es) | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
| US20070172514A1 (en) * | 2006-01-20 | 2007-07-26 | Francis Chi | Materials and methods for improving livestock productivity |
| DE102006010642A1 (de) * | 2006-03-08 | 2007-09-27 | Bayer Healthcare Aktiengesellschaft | Arzneimittelformulierungen, enthaltend Fluorchinolone |
| US20080035141A1 (en) * | 2006-06-16 | 2008-02-14 | Warner W R | Aerosolized therapy kit |
| KR20150041172A (ko) * | 2006-12-01 | 2015-04-15 | 래크리드 인코포레이티드 | 귀에서 균막을 용해시키기 위한 가수분해 및 산화 효소의 용도 |
| US20080131500A1 (en) * | 2006-12-04 | 2008-06-05 | The Board Of Regents Of The University Of Texas System | Methods and compositions for rapid inactivation of proteins |
| WO2008092262A1 (en) | 2007-01-31 | 2008-08-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Methods and compounds for treatment, prevention and diagnosis of parasitic infection and disease |
| GB0702021D0 (en) | 2007-02-02 | 2007-03-14 | Novabiotics Ltd | Peptides and their use |
| US9395352B2 (en) | 2007-04-06 | 2016-07-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Devices and methods for target molecule characterization |
| EP1994930A1 (en) * | 2007-05-22 | 2008-11-26 | Novartis AG | Triazol compounds for treating biofilm formation |
| RU2371447C2 (ru) * | 2007-10-05 | 2009-10-27 | Общество С Ограниченной Ответственностью "Саентифик Фьючер Менеджмент" | Конъюгат антибиотика и антибактериальное лекарственное средство на его основе |
| WO2009076722A1 (en) | 2007-12-19 | 2009-06-25 | The University Of Melbourne | Method of protecting a surface from biological fouling |
| BRPI0821985A2 (pt) * | 2008-01-10 | 2015-06-23 | Evonik Roehm Gmbh | Preparacao farmacêutica ou nutracêutica revestida tendo liberação de substância ativa controlada |
| BRPI0907561A2 (pt) | 2008-02-17 | 2015-08-04 | Walcom Animal Science I P 3 Ltd | Materiais e métodos para aperfeiçoamento da saúde de camarões |
| EP3695835A1 (en) * | 2009-02-03 | 2020-08-19 | Microbion Corporation | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
| GB0905451D0 (en) * | 2009-03-31 | 2009-05-13 | Novabiotics Ltd | Biofilms |
| US8815942B2 (en) * | 2010-10-20 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease |
| GB201021186D0 (en) | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
| WO2013103780A1 (en) | 2012-01-06 | 2013-07-11 | Trustees Of Boston University | Compositions and methods to boost endogenous ros production from bacteria |
| US20160106689A1 (en) | 2014-09-22 | 2016-04-21 | Novabiotics Limited | Use |
-
2010
- 2010-12-14 GB GBGB1021186.0A patent/GB201021186D0/en not_active Ceased
-
2011
- 2011-12-14 WO PCT/GB2011/001721 patent/WO2012080700A1/en active Application Filing
- 2011-12-14 DK DK15192845.4T patent/DK3040076T3/da active
- 2011-12-14 SG SG10201703290UA patent/SG10201703290UA/en unknown
- 2011-12-14 SI SI201131956T patent/SI3040076T1/sl unknown
- 2011-12-14 ES ES15192845T patent/ES2856831T3/es active Active
- 2011-12-14 SM SM201600121T patent/SMT201600121B/it unknown
- 2011-12-14 BR BR122019015601-8A patent/BR122019015601B1/pt active IP Right Grant
- 2011-12-14 PL PL11808253T patent/PL2651419T3/pl unknown
- 2011-12-14 ES ES11808253.6T patent/ES2565564T3/es active Active
- 2011-12-14 SG SG2013045612A patent/SG191146A1/en unknown
- 2011-12-14 LT LTEP15192845.4T patent/LT3040076T/lt unknown
- 2011-12-14 HU HUE11808253A patent/HUE027207T2/en unknown
- 2011-12-14 PT PT151928454T patent/PT3040076T/pt unknown
- 2011-12-14 KR KR1020137017966A patent/KR101955636B1/ko active IP Right Grant
- 2011-12-14 DK DK11808253.6T patent/DK2651419T3/en active
- 2011-12-14 PL PL15192845T patent/PL3040076T3/pl unknown
- 2011-12-14 RU RU2013131391A patent/RU2607660C2/ru not_active IP Right Cessation
- 2011-12-14 HU HUE15192845A patent/HUE053813T2/hu unknown
- 2011-12-14 EP EP11808253.6A patent/EP2651419B1/en active Active
- 2011-12-14 UA UAA201308670A patent/UA114470C2/uk unknown
- 2011-12-14 CN CN201180064011.0A patent/CN103732232B/zh active Active
- 2011-12-14 SG SG10201510095YA patent/SG10201510095YA/en unknown
- 2011-12-14 SI SI201130756A patent/SI2651419T1/sl unknown
- 2011-12-14 RU RU2016151115A patent/RU2739249C2/ru active
- 2011-12-14 AU AU2011343012A patent/AU2011343012C1/en not_active Ceased
- 2011-12-14 BR BR112013015010-6A patent/BR112013015010B1/pt active IP Right Grant
- 2011-12-14 JP JP2013543872A patent/JP5964854B2/ja active Active
- 2011-12-14 CA CA2821032A patent/CA2821032C/en active Active
- 2011-12-14 MX MX2013006873A patent/MX346664B/es active IP Right Grant
- 2011-12-14 RS RS20210194A patent/RS61469B1/sr unknown
- 2011-12-14 RS RS20160173A patent/RS54815B1/sr unknown
- 2011-12-14 NZ NZ613076A patent/NZ613076A/en unknown
- 2011-12-14 EP EP15192845.4A patent/EP3040076B1/en active Active
-
2012
- 2012-06-01 US US13/486,778 patent/US9782423B2/en active Active
-
2013
- 2013-06-11 IL IL226879A patent/IL226879B/en active IP Right Grant
- 2013-11-06 HK HK13112496.9A patent/HK1185015A1/zh not_active IP Right Cessation
-
2014
- 2014-08-15 US US14/460,953 patent/US9364491B2/en active Active
-
2016
- 2016-02-11 US US15/041,393 patent/US11020414B2/en active Active
- 2016-03-07 HR HRP20160235TT patent/HRP20160235T1/hr unknown
- 2016-03-18 CY CY20161100233T patent/CY1117447T1/el unknown
- 2016-06-30 JP JP2016129761A patent/JP6483058B2/ja active Active
- 2016-07-29 HK HK16109088.6A patent/HK1220911A1/zh unknown
-
2017
- 2017-03-10 AU AU2017201670A patent/AU2017201670B2/en active Active
-
2018
- 2018-12-17 AU AU2018282257A patent/AU2018282257A1/en not_active Abandoned
-
2020
- 2020-07-28 IL IL276342A patent/IL276342A/en unknown
-
2021
- 2021-02-17 CY CY20211100132T patent/CY1123951T1/el unknown
- 2021-02-18 HR HRP20210280TT patent/HRP20210280T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016151115A (ru) | Композиция, содержащая антибиотик и диспергирующее средство или антиадгезивный агент | |
| RU2011143399A (ru) | Ингибирование организмов биопленки | |
| JP2012522037A5 (ru) | ||
| US20220087963A1 (en) | Antimicrobial compositions and uses thereof | |
| JP2019189613A (ja) | 感染を制御するための材料および方法 | |
| JP2019048857A5 (ru) | ||
| WO2020201833A8 (en) | Gepotidacin for use in the treatment of bacterial urinary tract infections | |
| JP2011505340A5 (ru) | ||
| CA2706637A1 (en) | Use of alginate oligomers in combating biofilms | |
| JP2019104757A (ja) | 細菌性バイオフィルムを除去するためのセアプローゼの使用 | |
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| JP2012501349A5 (ru) | ||
| ES2390226T3 (es) | Tratamiento de enfermedades infecciosas | |
| EP2515869A2 (en) | Wound care products | |
| RU2014134720A (ru) | Противомикробные композиции, содержащие dgla, 15-онера и/или 15-hetre, и способы их применения | |
| JP2017519768A5 (ru) | ||
| WO2009033785A3 (en) | Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection | |
| JP2018500387A5 (ru) | ||
| JP2022111186A (ja) | 表面から細菌バイオフィルムを低減または除去するためのサーモリシンの使用 | |
| RU2018107150A (ru) | Новый эффективный аминогликозидный антибиотик против бактерий с множественной лекарственной резистентностью | |
| JP2024009968A5 (ru) | ||
| CA3139942A1 (en) | Medicament and use thereof for treating bacterial infections involving biofilm | |
| Wadhwa et al. | Exit-site care in peritoneal dialysis | |
| Kadirvelu et al. | A review on antimicrobial strategies in mitigating biofilm-associated infections on medical implants. | |
| Lee et al. | Successful treatment of recurrent methicillin-resistant staphylococcus aureus bacteremia and endocarditis by linezolid, valve replacement, and excisional surgery of limb in a patient with complicated arteriovenous malformation |